Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · Real-Time Price · USD
21.43
+0.61 (2.93%)
At close: Jun 6, 2025, 4:00 PM
21.43
0.00 (0.00%)
After-hours: Jun 6, 2025, 4:04 PM EDT
Fulgent Genetics Revenue
Fulgent Genetics had revenue of $73.46M in the quarter ending March 31, 2025, with 13.92% growth. This brings the company's revenue in the last twelve months to $292.45M, up 1.71% year-over-year. In the year 2024, Fulgent Genetics had annual revenue of $283.47M, down -1.99%.
Revenue (ttm)
$292.45M
Revenue Growth
+1.71%
P/S Ratio
2.24
Revenue / Employee
$222,733
Employees
1,313
Market Cap
652.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 283.47M | -5.74M | -1.99% |
| Dec 31, 2023 | 289.21M | -329.76M | -53.27% |
| Dec 31, 2022 | 618.97M | -373.62M | -37.64% |
| Dec 31, 2021 | 992.58M | 570.87M | 135.37% |
| Dec 31, 2020 | 421.71M | 389.18M | 1,196.46% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
FLGT News
- 15 hours ago - Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Shareholders to Inquire about Securities Investigation - Accesswire
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Investors to Connect - Accesswire
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Stockholders to Inquire about Securities Investigation - Accesswire
- 3 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Investors to Learn More About the Investigation - Accesswire
- 4 days ago - Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 7 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Stockholders to Connect - Accesswire
- 8 days ago - Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 9 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Stockholders to Learn More About the Investigation - Accesswire